论文部分内容阅读
目的:探讨对老年低位直肠癌患者采用新辅助治疗的临床效果。方法:收集64例老年低位直肠癌患者的临床资料,分为治疗组与对照组,各32例,治疗组在新辅助治疗后再行手术治疗;对照组仅行手术治疗。结果:治疗组的总有效率为87.50%,显著高于对照组的68.75%,有统计意义(P<0.05);治疗组的保肛率为87.50%;显著高于对照组56.25%,有统计意义(P<0.05);治疗组的毒副反应发生率为37.50%,显著低于对照组的81.25%,有统计意义(P<0.05);治疗组的3年生存率为75.00%,显著高于对照组37.50%,有统计意义(P<0.05);治疗组的3年复发率分别为12.50%,显著低于对照组的37.50%,有统计意义(P<0.05)。结论 :对老年低位直肠癌患者采用新辅助治疗,能有效提高患者的近期、远期疗效,且毒副反应较少、较轻,值得推广。
Objective: To investigate the clinical effect of neoadjuvant therapy on elderly patients with low rectal cancer. Methods: The clinical data of 64 elderly patients with low rectal cancer were collected and divided into treatment group and control group, with 32 cases in each group. The treatment group was treated with neoadjuvant therapy and the control group was treated with surgery alone. Results: The total effective rate of the treatment group was 87.50%, which was significantly higher than that of the control group (68.75%) (P <0.05). The anal sphincter preservation rate was 87.50% in the treatment group and 56.25% in the control group (P <0.05). The incidence of adverse reactions in the treatment group was 37.50%, which was significantly lower than 81.25% in the control group (P <0.05). The 3-year survival rate was 75.00% in the treatment group, which was significantly higher (P <0.05). The 3-year recurrence rates in the treatment group were 12.50%, which were significantly lower than those in the control group (37.50%, P <0.05). Conclusion: The neoadjuvant treatment of elderly patients with low rectal cancer can effectively improve the short-term and long-term effects of patients with less toxic side effects and is worth promoting.